

Title (en)

BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME

Title (de)

POSITIVE ALLOSTERISCHE MGLUR5-BENZAMIDMODULATOREN UND VERFAHREN ZU IHRER HERSTELLUNG UND VERWENDUNG

Title (fr)

DÉRIVÉS BENZAMIDES MODULATEURS ALLOSTÉRIQUES POSITIFS RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE 5 (MGLUR5) ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

Publication

EP 2162136 A4 20120215 (EN)

Application

EP 08770045 A 20080603

Priority

- US 2008065647 W 20080603
- US 94168607 P 20070603
- US 98504107 P 20071102

Abstract (en)

[origin: WO2008151184A1] In one aspect, the invention relates to compounds, including benzamide derivatives and cyclic benzamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC 8 full level

A61K 31/497 (2006.01)

CPC (source: EP KR)

A61K 31/166 (2013.01 - EP); **A61K 31/397** (2013.01 - EP); **A61K 31/40** (2013.01 - EP); **A61K 31/4035** (2013.01 - EP); **A61K 31/4245** (2013.01 - EP); **A61K 31/445** (2013.01 - EP); **A61K 31/4453** (2013.01 - EP); **A61K 31/451** (2013.01 - EP); **A61K 31/4523** (2013.01 - EP); **A61K 31/4535** (2013.01 - EP); **A61K 31/454** (2013.01 - EP); **A61K 31/4545** (2013.01 - EP); **A61K 31/47** (2013.01 - EP); **A61K 31/472** (2013.01 - EP); **A61K 31/4725** (2013.01 - EP); **A61K 31/4745** (2013.01 - EP); **A61K 31/495** (2013.01 - EP); **A61K 31/496** (2013.01 - EP); **A61K 31/497** (2013.01 - KR); **A61K 31/519** (2013.01 - KR); **A61K 31/5375** (2013.01 - EP); **A61K 31/5377** (2013.01 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07C 233/65** (2013.01 - EP); **C07C 233/66** (2013.01 - EP); **C07C 233/69** (2013.01 - EP); **C07D 205/04** (2013.01 - EP); **C07D 207/09** (2013.01 - EP); **C07D 209/46** (2013.01 - EP); **C07D 209/48** (2013.01 - EP); **C07D 211/18** (2013.01 - EP); **C07D 211/22** (2013.01 - EP); **C07D 211/42** (2013.01 - EP); **C07D 211/44** (2013.01 - EP); **C07D 211/46** (2013.01 - EP); **C07D 211/52** (2013.01 - EP); **C07D 211/58** (2013.01 - EP); **C07D 211/60** (2013.01 - EP); **C07D 213/74** (2013.01 - EP); **C07D 217/06** (2013.01 - EP); **C07D 217/24** (2013.01 - EP); **C07D 271/06** (2013.01 - EP); **C07D 295/13** (2013.01 - EP); **C07D 295/14** (2013.01 - EP); **C07D 295/192** (2013.01 - EP); **C07D 295/30** (2013.01 - EP); **C07D 401/04** (2013.01 - EP); **C07D 401/10** (2013.01 - EP); **C07D 401/12** (2013.01 - EP); **C07D 409/04** (2013.01 - EP); **C07D 413/12** (2013.01 - EP); **C07C 2601/02** (2017.04 - EP); **C07C 2601/08** (2017.04 - EP); **C07C 2601/14** (2017.04 - EP); **C07C 2602/08** (2017.04 - EP); **Y02A 50/30** (2017.12 - EP)

Citation (search report)

- [X] US 2006235069 A1 20061019 - DUGGAN MARK E [US], et al
- [I] WO 2005044797 A1 20050519 - ADDEX PHARMACEUTICALS SA [CH], et al
- [X] US 6656957 B1 20031202 - ALLGEIER HANS [DE], et al
- [X] WO 2006089700 A1 20060831 - NOVARTIS AG [CH], et al
- [X] WO 2005040144 A1 20050506 - GLAXO GROUP LTD [GB], et al
- [X] WO 2006093832 A2 20060908 - RENOVIS INC [US], et al
- [X] WO 03009807 A2 20030206 - GALILEO LAB INC [US]
- [X] EP 1748048 A1 20070131 - BANYU PHARMA CO LTD [JP]
- [X] WO 2004009549 A2 20040129 - ACTELION PHARMACEUTICALS LTD [CH], et al
- [X] WO 2005046683 A1 20050526 - RENOVIS INC [US], et al
- [A] DE PAULIS ET AL: "Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation on the metabotropic glutamate-5 receptor in rat cortical astrocytes", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 49, 1 January 2006 (2006-01-01), pages 3332 - 3344, XP008103364, ISSN: 0022-2623, DOI: 10.1021/JM051252J
- [T] SAMS A G ET AL: "Efficacy switching SAR of mGluR5 allosteric modulators: Highly potent positive and negative modulators from one chemotype", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 20110601 ELSEVIER LTD GBR LNKD- DOI:10.1016/J.BMCL.2011.03.103, vol. 21, no. 11, 1 June 2011 (2011-06-01), pages 3407 - 3410, XP002674409, ISSN: 0960-894X
- [T] RODRIGUEZ ALICE L ET AL: "Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity", MOLECULAR PHARMACOLOGY, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 78, no. 6, 1 December 2010 (2010-12-01), pages 1105 - 1123, XP008145887, ISSN: 0026-895X, [retrieved on 20101005], DOI: 10.1124/MOL.110.067207
- [T] ANDREAS RITZÉN ET AL: "Discovery of a potent and brain penetrant mGluR5 positive allosteric modulator", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 19, no. 12, 15 June 2009 (2009-06-15), pages 3275 - 3278, XP002664735, ISSN: 0960-894X, [retrieved on 20090424], DOI: 10.1016/J.BMCL.2009.04.095
- See references of WO 2008151184A1

Citation (examination)

A. BÖCKER ET AL: "GPCR Targeted Library Design: Novel Dopamine D3 Receptor Ligands", CHEMMEDCHEM, vol. 2, no. 7, 3 May 2007 (2007-05-03), pages 1000 - 1005, XP055082133, ISSN: 1860-7179, DOI: 10.1002/cmdc.200700067

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2008151184 A1 20081211; AU 2008259776 A1 20081211; AU 2008259776 A2 20100128; BR PI0812363 A2 20150203;
CA 2689282 A1 20081211; CN 101795689 A 20100804; CN 101795689 B 20141119; EA 200971143 A1 20100630; EP 2162136 A1 20100317;
EP 2162136 A4 20120215; HK 1147068 A1 20110729; IL 202508 A0 20100630; JP 2010529135 A 20100826; JP 5622568 B2 20141112;
KR 20100033981 A 20100331; MX 2009013169 A 20100430; NZ 581817 A 20120525; SG 185285 A1 20121129

DOCDB simple family (application)

US 2008065647 W 20080603; AU 2008259776 A 20080603; BR PI0812363 A 20080603; CA 2689282 A 20080603;
CN 200880100770 A 20080603; EA 200971143 A 20080603; EP 08770045 A 20080603; HK 11101174 A 20110207; IL 20250809 A 20091203;
JP 2010511277 A 20080603; KR 20097027281 A 20080603; MX 2009013169 A 20080603; NZ 58181708 A 20080603;
SG 2012074621 A 20080603